vandetanib: Clinical Trials

109 trials of vandetanib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

77 completed, 20 terminated, 5 withdrawn, 4 unknown. 59 Phase 2, 42 Phase 1, 9 Phase 3, 2 Not applicable, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 259Completed 39, Terminated 16, Unknown 2, Active not recruiting 1, Recruiting 1
Phase 142Completed 31, Terminated 7, Withdrawn 4
Phase 39Completed 7, Active not recruiting 1, Withdrawn 1
Not applicable2Unknown 2
Phase 41Completed 1

Follow vandetanib: new trials by email Literature Review of vandetanib trials Research Report on vandetanib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer
Phase 3WithdrawnHoffmann-La Roche2023-11-302024-01-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma
Phase 2RecruitingWest China Hospital752021-06-012024-12-05
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer
Phase 3Active not recruitingLoxo Oncology, Inc.2912020-02-112026-03-19
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary
Phase 2TerminatedH. Lee Moffitt Cancer Center and Research Institute62018-08-062021-07-14
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
CancerSCAN™, Ifosfamide, Carboplatin - Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor
Phase 2UnknownSamsung Medical Center902015-12-012020-03-19
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Vandetanib, Metformin, Vandetanib/Metformin - Renal Cell Carcinoma, Hereditary Leiomyomatosis
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)72015-08-262021-01-26
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Fulvestrant, Vandetanib - Neoplasms
Phase 2UnknownVelindre NHS Trust1602015-04-012015-08-21
Vandetanib in Advanced NSCLC With RET Rearrangement
Vandetanib - Non Small Cell Lung Cancer
Phase 2CompletedSamsung Medical Center172014-11-032020-12-07
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
Sunitinib, vandetanib, Erlotinib - Cancer, High-grade Glioma
Not applicableUnknownAmsterdam UMC, location VUmc152014-11-012020-10-08
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Vandetanib, 131I-mIBG - Phaeochromocytoma, Paraganglioma
Phase 1WithdrawnUniversity College, London2014-10-012015-12-21
N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
EMA-approved ATI based targeted therapy - Metastatic Cancer
Phase 2CompletedOslo University Hospital502014-05-012019-03-13
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
AZD2014, AZD4547, AZD5363 - Non-small Cell Lung Cancer Metastatic
Phase 2CompletedUNICANCER9992014-04-232024-01-10
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer
Phase 2Active not recruitingUNICANCER14602014-04-072025-01-15
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
Caprelsa - Metastatic Medullary Thyroid Cancer
CompletedGenzyme, a Sanofi Company102014-04-012017-05-02
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
Vandetanib 300 mg - Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
CompletedGenzyme, a Sanofi Company312014-02-172024-12-18
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Vandetanib - GIST
Phase 2CompletedNational Cancer Institute (NCI)92013-12-142020-03-30
A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
Erlotinib or Gefitinib, Everolimus, Imatinib - Gastrointestinal Cancers
Not applicableUnknownSun Yat-sen University502013-12-012016-08-30
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
Vandetanib, Placebo - Invasive Breast Cancer
Phase 2TerminatedRonald Weigel122013-10-012021-11-01
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
Vandetanib (SAR390530), Placebo - Differentiated Thyroid Cancer
Phase 3CompletedGenzyme, a Sanofi Company2382013-09-172024-07-23
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Vandetanib 300mg - Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Phase 1 / Phase 2CompletedGenzyme, a Sanofi Company142012-11-012016-12-05

Showing 20 of 109. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (24)  ·  Carcinoma, Medullary (14)  ·  Lung Neoplasms (14)  ·  Neoplasm Metastasis (12)  ·  Neoplasms (10)  ·  Breast Neoplasms (8)  ·  Thyroid Neoplasms (8)  ·  Glioma (6)  ·  Glioblastoma (5)  ·  Prostatic Neoplasms (5)  ·  Brain Neoplasms (4)  ·  Colorectal Neoplasms (4)  ·  Gliosarcoma (4)  ·  Squamous Cell Carcinoma of Head and Neck (4)  ·  Adenocarcinoma (3)

Sponsors

Genzyme, a Sanofi Company (37)  ·  Sanofi (10)  ·  National Cancer Institute (NCI) (9)  ·  M.D. Anderson Cancer Center (6)  ·  Dana-Farber Cancer Institute (4)  ·  Annick Desjardins (2)  ·  SWOG Cancer Research Network (2)  ·  Samsung Medical Center (2)  ·  St. Jude Children's Research Hospital (2)  ·  UNICANCER (2)  ·  University of Colorado, Denver (2)  ·  Amsterdam UMC, location VUmc (1)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Branimir Sikic (1)  ·  British Columbia Cancer Agency (1)

Countries

United States (63)  ·  Spain (16)  ·  France (15)  ·  Italy (15)  ·  United Kingdom (15)  ·  Germany (14)  ·  Canada (12)  ·  Belgium (11)  ·  South Korea (11)  ·  Netherlands (10)  ·  China (9)  ·  Australia (8)  ·  India (8)  ·  Brazil (7)  ·  Sweden (7)

Top investigators

Alberto Broniscer, MD (2)  ·  Brigitte C Widemann, M.D. (2)  ·  W. Marston Linehan, M.D. (2)  ·  Afshin Dowlati, MD (1)  ·  Anne Hansen Ree, Prof. MD PhD (1)  ·  Anne S. Tsao, MD (1)  ·  Annick Desjardins, MD (1)  ·  Annick Desjardins, MD, FRCPC (1)  ·  Branimir I Sikic (1)  ·  Carlos Jimenez, M.D. (1)  ·  Changhu Chen, MD (1)  ·  Christina Thirlwell (1)  ·  Christine H. Chung, M.D. (1)

Results publications

PMID 25117183, PMID 25881079, PMID 17878480, PMID 20068097, PMID 20570559, PMID 21035955, PMID 21247755, PMID 21282537, PMID 21282542, PMID 22025146, PMID 22586319, PMID 22701615, PMID 22898678, PMID 23442309, PMID 23553066, PMID 23689430, PMID 23766359, PMID 24005613, PMID 24617713, PMID 24709487, PMID 24913066, PMID 25057173, PMID 25503302, PMID 25538178, PMID 25972901, PMID 25982012, PMID 26291023, PMID 26410619, PMID 26715573, PMID 27803005, PMID 29187393, PMID 30297385, PMID 32067679, PMID 32208873, PMID 33075149, PMID 34292174, PMID 35165100, PMID 35943168, PMID 35969032, PMID 37185961, PMID 37870969, PMID 39516358, PMID 39694978, PMID 40304938, PMID 40617171, PMID 40785488

NIH funding

2005 (4), 2008 (1), 2014 (1), 2019 (1), P30CA022453 (1), P30CA043703 (1), U10CA032102 (1)